Determinants of time to access to EMA-approved cancer drugs in Spanish NHS in the past decade: a two cohorts study

Pelayo Nieto-Gómez, Celia Castaño-Amores, Antonio José García-Ruiz and Juan Oliva-Moreno

Health Policy, 2025, vol. 162, issue C

Abstract: Spain is the fourth largest pharmaceutical market in Europe, yet the time to reimbursement for cancer drugs has been considerably longer than in other European countries in recent years.

Keywords: Oncology; Access; Spain; Equity; Evidence based decision-making (search for similar items in EconPapers)
Date: 2025
References: Add references at CitEc
Citations:

Downloads: (external link)
http://www.sciencedirect.com/science/article/pii/S0168851025002246
Full text for ScienceDirect subscribers only

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:162:y:2025:i:c:s0168851025002246

DOI: 10.1016/j.healthpol.2025.105469

Access Statistics for this article

Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput

More articles in Health Policy from Elsevier
Bibliographic data for series maintained by Catherine Liu () and ().